GSK plc GSK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval of its ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis ...

London: GSK plc has announced the New Drug Application (NDA) for linerixibat, an investigational targeted inhibitor of the ...

US FDA accepts for review GSK’s NDA for linerixibat to treat cholestatic pruritus in patients with PBC: London, UK Tuesday, June 3, 2025, 11:00 Hrs [IST] GSK plc announced the U ...

Drugmaker GSK revealed on Monday that a new drug application for its linerixibat asset had been accepted for review by the US ...

Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC) · If approved, linerixibat could address high ...

(Alliance News) - GSK PLC on Monday announced the US Food & Drug Administration has accepted for review the new drug application for its liver disease treatment, linerixibat.

(RTTNews) - GSK plc (GSK) announced the FDA has accepted for review the NDA for linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter, for the treatment of ...

GSK plc (LSE/NYSE:LON:GSK) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for linerixibat, an investigational oral treatment targeting ...

The GLISTEN trial of GSK's linerixibat has shown that the oral ileal bile acid transporter (IBAT inhibitor was signposted as positive towards the end of last year, and the company has now revealed ...

GSK plc GSK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval of its investigational targeted inhibitor of the ileal bile acid transporter ...

Linerixibat has not yet been approved in any market, but both the FDA and the European Medicines Agency have granted it orphan drug designation for treating cholestatic pruritus in PBC patients.